Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy

Joshua Stoker⁎, Sujay Vora, Ameet Patel, David Grosshans, Paul D. Brown, Tamara Vern-Gross, Martin Bues, Thomas Daniels, Bryce Allred, Arielle Uejo, Heidi Kosiorek, Marlene Bruso, Sameer Keole

⁎ Corresponding author at: Mayo Clinic Arizona, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA.
E-mail address: stoker.joshua@mayo.edu (J. Stoker).

ARTICLE INFO
Keywords:
Intensity modulated proton therapy
Hippocampal sparing
Whole brain radiation therapy
RTOG 0933

ABSTRACT
Background and purpose: Intensity modulated proton therapy (IMPT) allows for modulation parameterized for individual beamlets by position, intensity, and depth. This modulation capability is ideally suited for sparing organs at risk intermediate of the radiation target, such as hippocampal volumes within the whole brain. This work compared IMPT relative to volumetric modulated arc therapy (VMAT) during hippocampal avoidance whole brain radiation therapy (HA WBRT).

Materials and methods: Ten adult and ten pediatric patients previously treated for central nervous system malignancies were identified. IMPT and VMAT treatment plans employing HA WBRT were generated for each patient, delivering 30 GyE (Gray Equivalent) in 10 fractions for adults and 36 GyE in 20 fractions for pediatrics. Dose indices, including dose volume histogram metrics and homogeneity index \( HI = \frac{[D_{5\%} - D_{95\%}]}{[D_{mean}]} \times 100 \), were used to assess plan quality and describe target coverage and normal-tissue sparing.

Results: IMPT offered significant benefits relative to VMAT for hippocampal sparing. Hippocampal mean dose was reduced from 13.7 ± 0.8 Gy with VMAT to 5.4 ± 0.3 GyE using IMPT for pediatrics, and was reduced from 11.7 ± 0.9 Gy with VMAT to 4.4 ± 0.2 GyE using IMPT for adults. IMPT similarly lowered left hippocampal mean dose. Dose to 95% of the clinical target volume was statistically equivalent for both groups; however, IMPT reduced the homogeneity index by roughly half.

Conclusion: This manuscript demonstrates that HA IMPT can match or exceed dosimetric benefits offered with modulated X-rays. Inclusion of IMPT in future prospective studies is warranted.

1. Introduction

The role of whole brain radiation therapy (WBRT) in the treatment of brain metastasis has evolved over the past decade. While there has been growing interest in the use of radiosurgery to treat metastasis, there are still indications for whole brain radiation therapy due to multiple metastatic sites, failed prior radiosurgery, leptomeningeal disease, and in patients with poor performance status. Much of the concern over WBRT relates to associated toxicities which include cognitive deficits, fatigue and diminished quality of life [1,2]. This paper presents the dosimetric advantages of using Intensity Modulated Proton Therapy (IMPT) during WBRT to reduce radiation-induced cognitive deficits, building on the Radiation Therapy Oncology Group (RTOG) study number 0933.

Radiation-induced brain injury can present as both anatomic and functional deficits, clinically expressed in terms of acute, early delayed, and late delayed injury [3]. Neurocognitive impairment remains a prominent side effect of cranial irradiation, impacting attention, executive function, information processing and memory [4–6]. Several hypotheses exist attempting to explain the pathophysiology of these injuries, including vascular damage, demyelination, deficits in neurogenesis etc.; however many questions remain [7]. Specific to cognitive decline, the hippocampus has emerged in recent years as a region potentially more sensitive to radiation therapy compared to other regions...
of the brain [8]. Human and animal studies have previously indicated a
dependence of cognitive function on neurogenesis; Olsson et al., ad-
ministered unilateral radiation to juvenile rat brains which demon-
strated a radiation-induced reduction to hippocampal volume and
neurogenesis [9]. Interference of adult neurogenesis within the hippo-
campus and stem cell recesses in the periventricular region is believed
to be associated with radiation-related cognitive deficits and regulation
of various neurocognitive functions: the subventricular zone laterally
along the lateral ventricle and the subgranular zone within the dentate
gyrus (DG) [1,10–14].

Radiotherapeutic dose to the hippocampi can be reduced using in-
tensity modulated radiation therapy. RTOG study number 0933 de-
monstrated hippocampal avoidance within the radiation treatment
plans with the goal of maintaining 100% of each hippocampus to less
than 9 Gy and maximal dose below 16 Gy, without significantly com-
promising treatment efficacy [15,16]. Utilizing these constraints, they
found that patients treated had an improvement in neurologic function
with mean relative decline in the Hopkins Verbal Learning Test-Delayed
Recall of 7% at 4 months compared to historical controls of 30% over
the same time period. Most recently, Tsai and colleagues demonstrated
stability neurocognitive outcomes in patients receiving hippocampal
sparring during WBRT following volumetric modulated arc therapy
(VMAT). At 4 months, functional preservation was significantly ob-
served in Wechsler Memory Scale-III Word List immediate recall with
the EQD2 ranging from a maximal dose of 12.6 Gy, to a minimal dose of
5.8 Gy delivered to both hippocampi [17]. Extension of hippocampal
avoidance to pediatric populations may yield matching or improved
results compared to previous adult studies.

Since this impetus was established, several other studies have in-
vested the optimal approaches for hippocampal sparing for various
diagnoses and treatment modalities [6,18–22]. To date, Tomotherapy
arguably has presented as the most compelling modality for hippo-
campal sparing [23] however, the capability of IMPT to spare the
hippocampal region during either whole or partial brain irradiation has
received only limited reporting [24]. With its capability to modulate
proximal and intermediate doses, in addition to distal target con-
formity, we hypothesized that IMPT is ideally suited to spare organs at
risk (OARs), such as hippocampi without compromising target volume
coverage.

2. Materials and methods

2.1. Study design

VMAT and IMPT plans were generated for ten adult and ten pe-
diatric patients consecutively identified from patients previously
treated at Mayo Clinic Arizona. All patients underwent computed to-
mography (CT)-based simulation in the supine position. The head and
upper neck were immobilized with a thermoplastic mask and contoured
headrest. The selected headrest ensured that posterior beams incident
upon the cranium were not subjected to sharp changes in radiological
path length. For pediatric patients requiring anesthesia, thermoplastic
masks were modified to allow for placement of nasal cannula. All pa-
tient data sets were anonymized prior to institutional review board
study approval.

Target structures as well as OARs were delineated by a staff radia-
tion oncologist, with the exception of hippocampi, which was deline-
ated by staff radiologist in accordance with RTOG/NRG guidelines
[25]. Contouring of the hippocampus was performed around the gray
matter (T1 hypo-intense) signal in the medial temporal lobe on thin
coronal and axial images. Although there are other sequences that allow
better differentiation between gray and white matter, the ubiquity of T1
weighted sequences on treatment planning scans makes them desirable.

2.2. Hippocampal anatomy

The hippocampus is a comma shaped structure along the medial
border of the temporal lobe consisting of the Cornu Ammonis
(Hippocampus Proper) and DG in an interlocking “u” configuration.
The lateral border was defined by the medial ependymal surface of the
temporal horn. The inferior border was delineated by the adjacent
gyrus as it borders the subiculum and CA1. The superior border was
defined by the choroidal fissure and fimbria. Posteriorly, it was
bounded by the splenium of the corpus callosum adjacent to the
quadrigeminal plate cistern. More anteroinferiorly, the medial border
was defined by the ambient cistern. The uncal recess of the temporal
horn helped differentiate the hippocampus from the amygdala.

The clinical target volume (CTV) consisted of the brain, including
meninges. The hippocampi, including a modality-specific planning
organ at risk volume (PRV) expansion, were excluded from the CTV. For
IMPT planning, pre-optimization spot placement was permitted within
a 0.8-cm expansion of the CTV, which allowed for 1 proton beam spot
outside the CTV. A dose-limiting annulus surrounding the CTV fa-
cilitated shaping the dose gradient outside the target. All adult plans
were normalized so that 95% of CTV received a 30 radiobiological Gray
Equivalent (GyE) dose, based on a 10-fraction course. Pediatric plans
were similarly normalized, except using 36 GyE delivered using a 20-
fraction course.

2.3. Field arrangement and beam parameters

VMAT plans consisted of two full arcs oriented coplanar to axial
patient plane, and two half arcs with their axes of rotation tilted an
equal but opposite 30 degrees along the coronal plane, such that the
half arcs are mirrored in the sagittal plane. VMAT plan constraints
were matched to RTOG 0933 planning requirements, and benchmarked
against Ref. [20]. RTOG 0933 planning constraints were scaled by
120% for pediatric cases to match the change in prescribed dose from
30 to 36 GyE. IMPT plans were generated using multi-field optimization
to meld dose distributions of a posterior-anterior field and a cranio-
caudal field angled 25 degrees anteriorly from patient vertex. IMPT
coverage of the CTV was subject to a 3% range and 2 mm setup un-
certainty robustness evaluation, requiring a worst-case 95% dose cov-
erage to 95%. The CTV was kept identical across both modalities to
validate dosimetric comparison. Each field used an acrylonitrile buta-
diene styrene range shifter with a water-equivalent thickness (WET) of
4.5 cm. The range shifter (ERS45) was mounted on a frame extended
from the proton nozzle. For a 117.1-MeV beam (10.0-cm WET range to
distal 80%) this extended position of the ERS45 results in an approxi-
ately 20% smaller beam sigma (8.0 mm vs. 10.2 mm) at isocenter
relative to a non-extended range shifter. Fluence and dose were de-
termined using the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA), with spot spacing based on an energy-depend-
ent lookup table.

2.4. Dosimetric evaluation

Patients were divided into adult and pediatric groupings. Plan
quality was evaluated by an homogeneity index derived from the
equation $H_I = [D_{95\%} - D_{95\%}]/[D_{mean}] \times 100$, where $D_{95\%}$ is the
dose-volume histogram (DVH) curve dose representing 95% of target
volume, and $D_{95\%}$ is the DVH curve dose representing 5% of target
volume. The ideal value for HI is 0, with increasing values for the
metric indicative of declining homogeneity throughout the volume.
Volumes of total CTV, as well as volumes of brain and cribriform plate
portions of the CTV receiving at least 95% of prescribed dose were also
recorded. Mean, along with maximum and/or minimum dose for hip-
campi, cochlea and lenses were also evaluated.
2.5. Statistical evaluation

Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc.). Significance was determined by Wilcoxon matched-pairs signed ranks test. The Wilcoxon matched-pairs signed ranks test is a nonparametric test which tests the equality of matched pairs of observations with the null hypothesis that both distributions are the same.

3. Results

The CTV D95% was statistically equivalent for both modalities for pediatrics and adults. However, VMAT delivery significantly increased the mean and maximum brain dose (see Table 1), resulting in a homogeneity indices that were roughly double when compared to IMPT for pediatrics and adults. Cross sectional anatomic views highlighting the relative homogeneities and proximity of the 50% isodose line to hippocampal structures are shown in Fig. 1 (pediatric) and Fig. 2 (adult).

IMPT offered significant benefit relative to VMAT for hippocampal, lens, and cochlear sparing. Table 2 highlights these significant improvements. These data are shown for a representative patient in Fig. 3. For Pediatric right hippocampal mean dose was reduced from 13.7 ± 0.8 Gy with VMAT to 5.4 ± 0.3 GyE for IMPT, with the left mean dose similarly reduced. IMPT also lowered adult right hippocampal mean dose from 11.7 ± 0.9 Gy with VMAT to 4.4 ± 0.2 GyE. Minimum and maximum hippocampal dose advantages observed for IMPT were of similar magnitude across both age groups. Lens dose was reduced by roughly 50% with IMPT, while maintaining cribriform plate coverage (see Tables 1 and 2). Dose sparing for the cochlea was statistically significant though less pronounced, dropping about 15–18% with IMPT.

4. Discussion

This manuscript represents the first published work to date highlighting the significant dosimetric impact IMPT can have on HA WBRT. Also of merit is the demonstrated capability of IMPT to maintain target coverage while substantially improving dose homogeneity within the whole brain target, as well as reducing dose to critical structures including cochlea and lenses. Somewhat deceptively, HI values for whole brain appear improved for VMAT; this is a product of the substantially lower hippocampal doses achieved with IMPT. The HI values reported for the CTV, which consists of the whole brain volume absent of the hippocampi, are a better indicator of the improved dose homogeneity achieved using IMPT.

Hippocampal sparing has demonstrated clinical benefit in

Table 1

| Target volume coverage and dose heterogeneity. | Pediatric patients | Adult patients |
|-----------------------------------------------|-------------------|---------------|
| Mean IMPT ± SD                               | Mean VMAT ± SD    |               |
| D5 (Gy or GyE) whole brain                   | 38.6 ± 0.4        | 32.0 ± 0.2    |
| D5 (Gy or GyE) CTV                           | 38.6 ± 0.4        | 32.1 ± 0.2    |
| D5 (Gy or GyE) brainstem                     | 38.6 ± 0.7        | 32.0 ± 0.3    |
| D95 (Gy or GyE) whole brain                  | 28.2 ± 3.0        | 23.9 ± 2.5    |
| D95 (Gy or GyE) CTV                           | 36.1 ± 0.3        | 30.0 ± 0.2    |
| D95 (Gy or GyE) brainstem                    | 27.7 ± 6.0        | 24.0 ± 6.5    |
| HI – whole brain                              | 28.9 ± 7.6        | 27.1 ± 8.0    |
| HI – CTV                                     | 6.8 ± 0.8         | 6.8 ± 0.4     |
| Mean (Gy or GyE) CTV                          | 37.3 ± 0.3        | 31.0 ± 0.2    |
| Mean (Gy or GyE) brainstem                   | 35.8 ± 1.0        | 29.9 ± 1.0    |
| V95% cribriform plate                        | 97.8 ± 2.3        | 98.1 ± 2.5    |

Abbreviations: DX% = Dose (GyE or Gy) received by at least X% of volume; CTV = clinical target volume; HI homogeneity index (D5%–D95%)/(mean dose) × 100; V95% = percentage of volume receiving at least 95% of prescribed dose. Data compared using Wilcoxon matched-pairs signed ranks test.

* Differences were significant (P < 0.05).
** Differences were highly significant (P ≪ 0.01).
preliminary studies. Gondi et al. prospectively investigated a potential predictive relationship between neurocognitive impairment and hippocampal dosimetric parameters. Hippocampi receiving less than 7.3 Gy to 40% volume demonstrated statistically significant cognitive benefit; this study demonstrates that IMPT achieves this important threshold with HA WBRT [26]. Currently an ongoing randomized trial is formally assessing the benefits of hippocampal sparing. This trial also builds upon a RTOG prospective randomized placebo controlled trial for patients with brain metastases receiving WBRT that found improved cognitive outcomes with memantine [27]. In a phase III trial, run by NRG, patients will be randomized to receive hippocampal avoidance WBRT with memantine or standard WBRT with memantine and neurocognitive function assessed at set time points. Patients eligible for this trial include patients with metastatic disease to the brain. If HA is shown to improve cognitive function and hence quality of life in survivors it may be expected that this would be adopted as standard of care; IMPT would be a preferred modality in this case, based on capability to deliver homogenous target dose amidst superior HA.

In addition to ongoing work at NRG, the current study assessed HA IMPT in patients treated for primary CNS malignancies. In general, these patients are expected to have superior survival outcomes when compared to patients treated for metastatic disease to the brain. Because cognitive decline typically progresses with time, such patients might be expected to benefit from HA IMPT to an even greater extent. Also, unique to our study is the inclusion of pediatric patients. Pediatric patients are especially sensitive to the radiation induced cognitive deficits, perhaps much more so than adult patients [28]. Here again the cognitive and quality of life benefits of HA IMPT in pediatric patients could be substantial. A recent study recently reported a significant
association between the hippocampus volume receiving 20 Gy E. However, it is important to note that HA either with photon or IMPT would carry the risk of increased rates of disease recurrence within the excluded volumes [28]. Hence such studies would have to be done as part of prospective clinical trials with built in early stopping rules and close attention payed to patterns of failure in order to ensure that disease control was not significantly compromised.

On a technical note, accurate delineation of the hippocampi is necessary in order to achieve intended clinical outcomes. A recent review reported on various deviations identified from the Quality Assurance Results of RTOG 0933 [29]. Of 113 physicians, eight (6.8%) failed hippocampal contouring on 1st attempt; with only three of the eight achieving approval on the 2nd attempt. However, with the availability of a hippocampal atlas and continuing instruction, one would hope for hippocampal contouring on 1st attempt; with only three of the eight physicians achieving approval on the 2nd attempt.

This is the first work to assess the benefits of HA using IMPT in pediatric primary brain tumor patients requiring WBRT. This manuscript demonstrates that HA IMPT can match or exceed dosimetric benefits offered with modulated X-rays. This increased dosimetric benefit to OAR may warrant inclusion of the IMPT modality as part of any upcoming clinical investigations into hippocampal avoidance for pediatric populations.

Conflict of interest

The authors certify that they have no affiliations or involvement in any organization or entity with any financial interest relating to the subject matter herein.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.phro.2018.11.001.

References

[1] Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero SW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCTG N107/C-EC): 3: a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:1049–60.

[2] Chow E, Davis L, Holden L, Tsao M, Danjoux C. Prospective assessment of patient-reported symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage 2005;30:18–23.

[3] Constine LS, Konski A, Eikhom S, McDonald S, Rubin P. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 1988;15:319–30.

[4] Packer RJ, Sutton LN, Atkins TE, Radcliffe J, Bunin GR, D’Angio G, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 1989;70:707–13.

[5] Copeland DR, Fletcher JM, Pfefferbaum-Levine B, Jaffe N, Ried H, Maor M. Neuropsychological sequelae of childhood cancer in long-term survivors. Pediatrics 1985;75:745–53.

[6] Proek V, Wiedemann N, Pels F, Schmucker M, Nieder C, Grousou AL. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys 2012;85:264–70.

[7] Chan KC, Khoi PL, Cheung MM, Wang S, Cai KX, Wu EX. MRI of late micro-structural and metabolic alterations in radiation-induced brain injuries. J Magn Reson Imaging 2009;29:1013–20.

[8] Mitje ML, Minamata S, Fisher JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med 2002;8:955–62.

[9] Olsson E, Ekerestrom C, Berg G, Borga M, Ekholm S, Johansson G, et al. Hippocampal volumes in patients exposed to low-dose radiation to the basal brain. A case-control study in long-term survivors from cancer in the head and neck region. Radiat Oncol 2012;7:202.

[10] Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008;132:645–60.

[11] Bonaguidi MA, Song J, Ming GL, Song H. A unifying hypothesis on mammalian neural stem cell properties in the adult hippocampus. Curr Opin Neurobiol 2012;22:76–81.

[12] Greene-Schloesser D, Moore E, Robbins ME. Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res 2013;19:2294–300.

[13] Cheng Z, Li YQ, Wong CS. Effects of aging on hippocampal neurogenesis after irradiation. Int J Radiat Oncol Biol Phys 2016;94:1181–9.

[14] Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313–7.

[15] Gondi V, Tome WA, Marsh J, Struck A, Giaia A, Turian JV, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 2010;95:327–31.

[16] Gondi V, Pugh SL, Tome WA, Caene C, Conr B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 2014;32:3810–6.

[17] Tsai PF, Yang CC, Chuang CC, Huang TY, Wu YM, Pui PC, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study. Radiat Oncol 2015;10:253.

[18] Padovani L, Chapon F, Andre N, Borelumeke M, Geoffray A, Bourdeau F, et al. Hippocampal sparing during craniospinal irradiation: what did we learn about the incidence of perihippocampal metastases? Int J Radiat Oncol Biol Phys 2018;100:986–9.

[19] Zhang L, Antonie J, Li J, Saha S, Riegel AC, Vrijen L, et al. Hippocampal-sparing and target volume coverage in treating 3 to 10 brain metastases: a comparison of Gamma Knife, single-isocenter VMAT, CyberKnife, and TomoTherapy stereotactic radiosurgery. Pract Radiat Oncol 2017;7:183–9.

[20] Gondi V, Tolakanahalli R, Mehta MP, Tewadia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: a “how to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:1244–52.

[21] Hsu F, Carolan H, Nichol A, Cao F, Nuroney N, Lee R, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1–3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2010;76:1480–5.

[22] Pinkham MB, Bertrand KC, Olson S, Zarate D, Orum J, Pullar A, et al. Hippocampal-sparing radiotherapy: the new standard of care for World Health Organization grade II and III gliomas? J Clin Neurosci 2014;21:86–90.

[23] Gutierrez AN, Westerly DC, Tome WA, Jaradat HA, Mackie TR, Bentzen SM, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 2007;69:589–97.

[24] Brodin NP, Munck af Rosenschold P, Blomstrand M, Kiil-Berthelsen A, Hollensen C, Vogelius IR, et al. Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro Oncol 2014;16:594–602.

[25] Carran JR, Wu, Dissa PJ, Wolmark N. NR8 Oncology research opportunities within the new National Clinical Trials Network. Semin Oncol 2014;41:553–5.

[26] Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function improvement after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 2012;83:e487–93.

[27] Brown PD, Pugh S, Laack NN, Weisel JS, Khuntia D, Meyers C, et al. Mecamantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013;15:1429–37.

[28] Zureick AH, Evans CL, Niemierko A, Grieco JA, Nichols AJ, Fullerton BC, et al. Left hippocampal sparing radiotherapy for pediatric medulloblastoma: new oncologic treatment options. J Neurosurg Pediatr 2018;19:28–32.

[29] Gondi V, Cui Y, Mehta MP, Manfredi D, Xiao Y, Galvin JM, et al. Real-time pre-treatment review limits unacceptable deviations on a cooperative group radiation therapy technique trial: quality assurance results of RTOG 0933. Int J Radiat Oncol Biol Phys 2015;91:564–70.